As most of intracellular
reactive oxygen species (ROS) is produced in the mitochondria, mitochondrial modulation of
cancer cell is a promising strategy for maximizing the in situ-activable combination
therapy of oxidative catastrophe and cascaded
chemotherapy. Herein, a serum-stable polymer‑calcium
phosphate (CaP) hybrid
nanocapsule carrying
siRNA against
ADP-ribosylation factor 6 (Arf6) overexpressed in
cancer cells and parent drug
camptothecin (
CPT), designated as PTkCPT/
siRNA, was developed for the RNAi-induced oxidative catastrophe and cascaded
chemotherapy. A copolymer of
mPEG-P(Asp-co-TkCPT), covalently tethered with chemotherapeutic
CPT via a ROS-labile dithioketal (Tk) linker, was synthesized and self-assembled into a PTkCPT
micelle as a nanotemplate for the CaP mineralization. The as-prepared PTkCPT/
siRNA nanoparticle showed a core-shell-distinct
nanocapsule which was consisted of a spherical polymeric core enclosed within a CaP shell capable of releasing
siRNA in response to lysosomal acidity. Blocking Arf6 signal pathway of
cancer cells led to their mitochondrial aggregation and subsequently induced a burst of ROS for oxidative catastrophe, which further triggered the cascaded
CPT chemotherapy via the breakage of ROS-labile dithioketal linker. This strategy of RNAi-induced oxidative catastrophe and cascaded
chemotherapy resulted in a significant combination effect on
cancer cell killing and
tumor growth inhibition in mice with low side effects, and provided a promising paradigm for precise
cancer therapy.